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Abstract
Background: Diagnosis costs for cardiovascular disease waste a large amount of healthcare
resources. The aim of the study is to evaluate the clinical and economic outcomes of alternative
diagnostic strategies in low risk chest pain patients.
Methods:  We evaluated direct and indirect downstream costs of 6 strategies: coronary
angiography (CA) after positive troponin I or T (cTn-I or cTnT) (strategy 1); after positive exercise
electrocardiography (ex-ECG) (strategy 2); after positive exercise echocardiography (ex-Echo)
(strategy 3); after positive pharmacologic stress echocardiography (PhSE) (strategy 4); after positive
myocardial exercise stress single-photon emission computed tomography with technetium Tc 99m
sestamibi (ex-SPECT-Tc) (strategy 5) and direct CA (strategy 6).
Results: The predictive accuracy in correctly identifying the patients was 83,1% for cTn-I, 87% for
cTn-T, 85,1% for ex-ECG, 93,4% for ex-Echo, 98,5% for PhSE, 89,4% for ex-SPECT-Tc and 18,7%
for CA. The cost per patient correctly identified results $2.051 for cTn-I, $2.086 for cTn-T, $1.890
for ex-ECG, $803 for ex-Echo, $533 for PhSE, $1.521 for ex-SPECT-Tc ($1.634 including cost of
extra risk of cancer) and $29.673 for CA ($29.999 including cost of extra risk of cancer). The
average relative cost-effectiveness of cardiac imaging compared with the PhSE equal to 1 (as a cost
comparator), the relative cost of ex-Echo is 1.5×, of a ex-SPECT-Tc is 3.1×, of a ex-ECG is 3.5×,
of cTnI is ×3.8, of cTnT is ×3.9 and of a CA is 56.3×.
Conclusion:  Stress echocardiography based strategies are cost-effective versus alternative
imaging strategies and the risk and cost of radiation exposure is void.
Introduction
Technological advances in cardiac imaging have led to
dramatic increase in test utilization and in cardiovascular
healthcare costs [1-3]. Cardiac imaging is a major contrib-
utor to rising healthcare costs with estimates of more than
9.3 million myocardial perfusion procedures performed
in 2002 in the United States (US) [4] and a growth of 40%
in the last 3 years [5]. Each test represents a cost, as well as
a potential risk, as biohazards and downstream long-term
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costs linked to radiation exposure should also be consid-
ered [5].
Several current tests for the diagnosis of coronary artery
disease are more expensive and more accurate than tradi-
tional ex-ECG [6-8]. Little information exists to guide the
clinician about which test to order or to inform policy
makers about which tests represent the best value. Despite
several meta-analyses, the effectiveness of these proce-
dures, defined using prognostic value each test's, has been
reported in several observational studies, but limited
comparative data are available in similarly at-risk popula-
tions [9-11]. Substantial cost saving could be realized if health
care policies allocate resource use on the basis of both clinical
outcomes and cost effectiveness data and it would be necessary
a combined clinical and cost effectiveness-driven testing strat-
egy in patients with suspected coronary artery disease. Ex-ECG,
stress myocardial SPECT with thallium (Th) or techne-
tium (Tc), and more recently, PhSE, ex-Echo and CA have
been used to detect unstable angina (UA) and to identify,
among patients referred for suggestive coronary artery dis-
ease, those at risk of coronary events [7]. Ex-ECG is con-
sidered the standard reference test to investigate the cause
of chest pain that suggests coronary origin, where stress
imaging testing (stress echocardiography, stress myocar-
dial SPECT) and CA are the second and third choice
[7,12]. However, while the cost of ex-ECG is lower [12],
the accuracy of other imaging tests is also claimed to be
higher [6,7,9-11]. This is a scenario where an economic
evaluation could help in choosing a diagnostic test, since
from the clinical point of view, is not enough that a test is
marginally "better" than the other to justify its use: the
extra-value should be proportional to the extra-cost and to
the extra-risk.
Methods
In order to explore the relative merit of the tests in diag-
nosing coronary disease, we evaluated the overall clinical
and economic outcomes of diagnostic strategies in simi-
larly at-risk populations, i.e. in low- intermediate risk
chest pain patients including downstream long-term risks
and costs linked to radiation exposure by ionizing imag-
ing testing. For this purpose, we investigated the cost-
effectiveness of ex-ECG and four imaging modalities used
in this setting in comparison with serum markers of myo-
cardial injury. From a methodological viewpoint, we
made an analysis to obtain an approximate estimate of
the relative cost-effectiveness starting from the approxi-
mate relative costs of the tests and we evaluated the eco-
nomic implications of the different strategies. A decision
analytical model with six branches, each representing a
treatment strategy for chest pain patients was created and
the results of four studies, where different strategies were
applied, have been analysed. For non-invasive strategies
we selected studies including a wide number of patients
and outcome analysis at six-twelve months follow-up.
Study population
The population was defined as patients presenting to
emergency department (ED) with acute chest pain unex-
plained by trauma or chest radiological findings and:
1. no electrocardiogram (ECG) changes diagnostic of
acute myocardial infarction (AMI) or UA;
2. no evidence of other serious abnormality requiring hos-
pital admission;
3. no clinically obvious UA, defined as known coronary
artery disease with prolonged or recurrent episodes of car-
diac type chest pain.
Potential strategies
The following strategies were considered:
1. observation and serum markers of myocardial injury
(cTnI and cTnT) [13,14];
2. observation, serum markers of myocardial injury and
ex-ECG [13];
3. observation, serum markers of myocardial injury and
ex-Echo [13];
4. observation, serum markers of myocardial injury and
PhSE [15];
5. observation, serum markers of myocardial injury and
ex-SPECT with Tc 99m Tc sestamibi or Tc 99m tetrofos-
mine [13];
6. observation, serum markers of myocardial injury and
direct CA [16].
Test characteristics and performance
Diagnostic accuracy
Head to head comparison of performance of c-TnI, ex-
ECG, ex-Echo and ex-SPECT-Tc showed that the sensitivity
was 24%, 43%, 85%, 86%, the specificity was 99%, 95%,
95%, 90%, the diagnostic accuracy 85%, 85%, 93%, 89%
for c-TnI, ex-ECG, ex-Echo and for ex-SPECT-Tc respec-
tively [13]. In the Stress Pharmacological Echocardiogra-
phy in Emergency Department (SPEED) trial PhSE had
the greatest specificity (96%) [15]. PhSE, and expecially
dipyridamole stress echo, and ex-Echo are more feasible
and have better sensitivity than ex-ECG, like that myocar-
dial SPECT, and higher specificity than nuclear imaging
(96–95% versus 90% respectively) for coronary artery dis-
ease (CAD) identification [9-11]. De Filippi et al. com-Cardiovascular Ultrasound 2008, 6:21 http://www.cardiovascularultrasound.com/content/6/1/21
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pared a strategy of pre-discharge CA with ex-ECG in low-
intermediate risk chest pain patients. CA showed disease
in 19% and ex-ECG was positive in 7% of patients [16].
Feasibility
The feasibility of ex-ECG stress testing is 79% [17,18]. For
ex-Echo the feasibility is better and PhSE has higher feasi-
bility (99% dipyridamole, 94% dobutamine and in the
ED setting 97%) [15]. Myocardial SPECT has the same fea-
sibility but the availability is limited especially in the ED.
Prognostic Value
In the study by Conti et al. the negative predictive value
was 85%, 97%, 97%, 88% and the positive predictive
value was 81%, 81%, 67%, 66% for c-TnI, ex-Echo, ex-
SPECT-Tc and ex-ECG respectively [13]. The positive pre-
dictive value of c-TnT was 90% for CAD identification and
32,4% for coronary events and the negative predictive
value for coronary events was 87% at 1-year follow-up
[14]. In the SPEED trial positive PhSE had high predictive
value for all events (78%) and revascularization (76%).
The negative predictive value was 98,8% for all events and
99,6% for hard events, myocardial infarction (MI) and
coronary death (CD) at 13 months follow-up [15].
Cost-effectiveness analysis
The cost-effectiveness analysis of different non-invasive
strategies has to be evaluated with a prognostic-based
approach.
Predictive Accuracy
We retrospectively evaluated the costs and the clinical out-
come if 1 of 6 strategies had been used to further investi-
gate and consequently treat low-intermediate chest pain
patients. Standard protocols have been used for ex-ECG,
ex-Echo, PhSE, and ex-SPECT-Tc [8,19,13]. Spontaneous
coronary events, i.e., CD, MI, Heart Failure (HF) and UA
requiring hospitalization were considered. The rate of
normal coronary angiograms among patients with posi-
tive results was also considered. A patient was termed cor-
rectly identified by a strategy if he or she had a negative
result and no event during the follow-up; a patient was
also termed correctly identified by a strategy if he or she
had positive result and abnormal coronary arteries at CA.
The predictive accuracy was the percentage of patients cor-
rectly identified by each strategy [8].
Economic evaluation (Table 1)
Cost-effectiveness analysis was performed as previously
suggested [20] and according to the guidelines for authors
and peer reviewers of economic submission to BMJ [21].
Only waste costs (i.e. costs not associated to a proven clin-
ical benefit) were taken into account for the economic
evaluation. Accordingly, the cost of each strategy was cal-
culated by adding the cost of the test or tests and that of
unpredicted events (i.e. CD, MI, HF and UA) for patients
with a negative result or the finding of normal coronary
arteries for patients with a positive result. Finally, the
extra-risk of lifetime fatal and non-fatal cancer was calcu-
lated when present and the additional cost was added to
the cost of each strategy [5,22-29].
1) Direct costs (Table 1)
Average cost of cardiac imaging
The absolute costs of diagnostic tests have a wide geo-
graphical variation, but the average relative costs can be
applied in various locations. For stress cardiac imaging,
compared with the ex-ECG equal to 1 (as a cost compara-
tor), approximately the relative cost of stress echocardiog-
raphy is 2.1×, of a stress SPECT scintigraphy is 5.7× and of
CA is 21.7×. [12] (Figure 1). Assuming the cost of ex-ECG
is 140$, that of a stress echocardiography will be 294$, of
a stress myocardial SPECT 798$, and of a CA 3038$.
Table 1: Costing data of tests, clinical events and coronary angiography
Direct Costs Indirect Costs
Relative 3 Absolute Events Morbidity Mortality Overall
c-TnT or I 13,504
treadmill exercise test 1 140
stress echocardiography 2.1× 294
SPECT scintigraphy 5.7× 798
Coronary Angiography 21.7× 3038
Unstable Angina 10.3013 5101 10.811
Acute Myocardial Infarction 16.7813 11.5021 28.283
Heart Failure 14.0901 11.5021 25.592
Cardiac Death 10.4145 114.4841 124.898
Fatal Cancer 50.5492 12.3092 75.3872 138.246
Non Fatal Cancer 50.5492 12.3092 62.858
Costs are expressed in US dollars years 20031, 20042, 1999–20013, 19974, 20005Cardiovascular Ultrasound 2008, 6:21 http://www.cardiovascularultrasound.com/content/6/1/21
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Cost of c-TnT or c-TnI
The cost of c-TnT or c-TnI assay was charged 13, 50$
according to cost analysis of ED triage strategies for acute
chest pain and 3 assays were performed according to chest
pain guidelines [30,31].
2) Indirect costs (Table 1)
Average cost of unpredicted events
Coronary clinical events have been charged according to
the American Heart Association Statistical Update 2006
[32] and to recent cost analysis of acute coronary syn-
drome in a managed care setting [33]. Direct cost of CD
has been charged according to DRG 123 (2000 Medicare
diagnosis related group DRG values). All costs are
expressed in US dollars. Direct medical costs were about
$10.414 for CD, $16.781 for MI, $10.301 for UA and
$14090 for HF [32]. Indirect morbidity costs (lost produc-
tivity for morbidity) are about $11.502 per patient for MI
and HF (morbidity due to long-term disability), $510 for
angina and UA (morbidity due to short-term disability)
[34]. The indirect mortality costs (lost productivity for
premature death) are $114.484 (lost of mean 14 year of
life) [32].
Economic and biological costs of cardiac imaging
The radiation exposure is zero for ex-ECG, ex-Echo and
PhSE, and corresponds to 300 chest x rays (6 millisievert)
(mSv) for a CA, and to 500 chest x rays (10 mSv) for a Tc
cardiac stress scan [24,25]. In order to calculate risk, esti-
mates of fatal cancer were taken from ICRP (International
Commission on Radiological Protection), [26] and esti-
mates of cancer (fatal and non fatal) from BEIR VII (Bio-
logic Effects of Ionizing Radiation VII) [28]. The
corresponding extra-risk in a lifetime of fatal cancer is 1 in
2.000 exposed patients when the extra-risk of cancer (fatal
and non fatal) is 1 in 1000 exposed patients for 10 mSv
exposure
The extra-cost of cancer was estimated according to the
National Institutes of Health U.S. 2004 values. Overall
costs for fatal cancer were $138.246 per patient: $50.549
for direct medical costs (total of all health expenditures);
$12.309 for indirect morbidity costs (cost of lost produc-
tivity due to illness); and $75.387 for indirect mortality
costs (cost of lost productivity due to premature death
with lost of mean 14 years of life). The overall costs for
non-fatal cancer were $62.858. [35]. Currently is difficult
to estimate the costs induced by the risk of radiation –
induced teratogenesis which represents a fifth of the risk
of fatal cancer. [5,22-29]
Cost per patient correctly identified
The cost per patient correctly identified was calculated as
the ratio between the overall cost of each strategy and the
number of patients correctly identified by the correspond-
ing strategy. The economic analysis was rated to 1000
patients evaluated.
Results
The predictive accuracy was 83,1% for cTnI, 87% for cTnT
85,1% for ex-ECG, 93,4% for ex-Echo, 98,5% for PhSE,
89,4% for ex-SPECT-Tc and 18,7% for CA (Figure 2). In
fact the strategy based on cTnI and cTnT test would have
correctly identified the follow-up of 831 of 1.000 patients
and 870 of 1.000 respectively versus 851 of 1.000 patients
correctly identified by ex-ECG, 934 of 1.000 by ex-Echo,
Average relative cost of cardiac imaging when compared with  exercise electrocardiography Figure 1
Average relative cost of cardiac imaging when com-
pared with exercise electrocardiography. Exercise = 
exercise electrocardiography; stress echo = pharmacological 
and exercise echocardiography; SPECT = myocardial stress 
single-photon emission computed tomography with techne-
tium Tc 99m sestamibi; CA = coronary angiography.
Predictive accuracy of Troponin and Cardiac Imaging Figure 2
Predictive accuracy of Troponin and Cardiac Imag-
ing. cTn-I = troponin I; cTnT = troponin T; ex-ECG = exer-
cise electrocardiography; ex-Echo = exercise 
echocardiography; PhSE = pharmacologic stress echocardiog-
raphy; ex-SPECT = myocardial exercise stress single-photon 
emission computed tomography with technetium Tc 99m 
sestamibi; CA = coronary angiography).Cardiovascular Ultrasound 2008, 6:21 http://www.cardiovascularultrasound.com/content/6/1/21
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985 of 1.000 by PhSE, 894 of 1.000 by ex-SPECT-Tc and
187 of 1.000 by CA. The costs of the strategy and the costs
per patient correctly identified result $1.704.161 and
$2.051 for cTnI, $1.814.482 and $2.086 for cTnT,
$1.608.327 and $1.890 for ex-ECG, $750.282 and $803
for ex-Echo, $525.495 and $533 for PhSE, $1.359.953
and $1.521 for ex-SPECT-Tc ($1.634 including cost of
extra risk of cancer) and $5.548.794 and $29.673 for CA
($29.999 including cost of extra risk of cancer) (Figure 3)
(Table 2). The average relative cost-effectiveness of cardiac
imaging compared with the PhSE equal to 1 (as a cost
comparator), the relative cost of ex-Echo is 1.5×, of a ex-
SPECT-Tc is 2,9× and 3.1× including cost for extra risk of
cancer, of a ex-ECG is 3.5×, of cTnI is ×3.8, of cTnT is ×3.9
and of a CA is 56× and 56,3× including cost for extra risk
of cancer (Figure 4).
Discussion
As a leading cause of mortality and morbidity, CAD
remains a field of innovation to improve health out-
comes. In the US, there have been substantial increases in
the utilization of procedures for the diagnosis and treat-
ment of coronary artery disease from 1993 to 2001 and
total costs of cardiac procedures nearly doubled [36,37].
Increases in procedure rates over time continue to grow
steadily and were dramatically pronounced for stress
imaging studies, cardiac catheterizations, and coronary
angioplasty. The increases were not uniform across proce-
dures: there was a nearly 3-fold increase in the use of radi-
onuclide imaging stress tests and a modest decline in
nonimaging stress tests, percutaneous coronary angi-
oplasty (PCI) doubled and coronary artery bypass grafting
Costs per patient correctly identified with extra cost for can- cer risk Figure 3
Costs per patient correctly identified with extra cost 
for cancer risk. cTn-I = troponin I; cTnT = troponin T; ex-
ECG = exercise electrocardiography; ex-Echo = exercise 
echocardiography; PhSE = pharmacologic stress echocardiog-
raphy; ex-SPECT = myocardial exercise stress single-photon 
emission computed tomography with technetium Tc 99m 
sestamibi; CA = coronary angiography.
Table 2: Costs per strategy
Strategy Costs per strategy($) Costs per patient 
correctly identified ($)
Costs per radiation 
exposure($)
Total Costs per 
strategy($)
Costs per patient 
correctly identified ($)
1. cTnI 1.704.161 2.051 0 1.704.161 2.051
cTnT 1.814.482 2.086 0 1.814.482 2.086
2. ex-ECG 1.608.327 1890 0 1.608.327 1.890
3. ex-Echo 750.282 803 0 750.282 803
4. PhSE 525.495 533 0 525.495 533
5. ex-SPECT-TcS 1.359.953 1521 100.552* 1.460.505 1.634
6. CA 5.548.794 29.673 60.939** 5.609.733 29.999
Costs are expressed in US dollars
* per 1000 patients ($101 per patient)
** per 1000 patients ($61 per patient)
The average relative cost-effectiveness of cardiac imaging  when compared with pharmacologic stress echocardiography Figure 4
The average relative cost-effectiveness of cardiac 
imaging when compared with pharmacologic stress 
echocardiography. cTn-I = troponin I; cTnT : troponin T; 
ex-ECG = exercise electrocardiography; ex-Echo = exercise 
echocardiography; PhSE = pharmacologic stress echocardiog-
raphy; ex-SPECT = myocardial exercise stress single-photon 
emission computed tomography with technetium Tc 99m 
sestamibi; CA = coronary angiography.Cardiovascular Ultrasound 2008, 6:21 http://www.cardiovascularultrasound.com/content/6/1/21
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(CABG) was unchanged [37]. This increase is unlikely to
be related to an increase in underlying disease prevalence,
since the rate of hospitalization for AMI in the same pop-
ulation has been nearly constant [37,38]. Rates of radio-
nuclide imaging could suggest that the use has become
much less focused and these imaging studies have become
the standard of clinical practice in the risk stratification
after AMI, PCI and CABG, although data to support their
routine use in place of ex-ECG or stress echocardiography
appear not yet conclusive [4,12,37,38]. The impact may
be minimal for many patients, deleterious for some
patients, and costly for society. In the ideal healthcare sys-
tem, to minimize waste and to maximize efficiency, it is
essential to consider the appropriateness and outcomes of
cardiac procedures.
More costly, more effective techniques are worth 
substituting for the older, less costly, less effective 
technique?
The cost of alternative strategies to evaluate patients with
chest pain depends on: 1) cost of cardiac imaging, 2) sen-
sitivity, specificity and diagnostic accuracy, 3) feasibility,
4) prognostic value 5) individual and social risk of imag-
ing. Ex-ECG and stress imaging has been used to detect UA
and the risk of coronary events. Ex-ECG was the obvious
first choice, due to its simplicity, widespread availability,
and low cost. Stress imaging can be nuclear perfusion or
stress echo imaging; many data suggest that the latter has
comparable accuracy, feasibility, negative predictive
value, higher diagnostic specificity and the obvious
advantages of no environmental impact, lower cost, no
known biohazards for the patients and do not imply the
use of particular structures at high cost like a nuclear med-
icine service [15]. The high diagnostic specificity for stress
echocardiography could minimize cost waste in the
lower-intermediate risk patient. The CA strategy is not
cost-effective because of high probability of normal coro-
nary artery (81%) in this group of patients and is consid-
ered inappropriate because of the risks and the costs it
implies [16]. As well direct CA results in a greater fre-
quency of revascularization, without an added outcome
benefit [36].
The average relative cost-effectiveness of cardiac imaging
compared with the PhSE equal to 1 (as a cost compara-
tor), approximately the relative cost of ex-Echo is 1.5×, of
a stress SPECT-Tc is 3.1×, of a ex-ECG is 3.5×, of cTnI is
×3.8, of cTnT is ×3.9 and of CA ×56,3 (Figure 4). The indi-
rect costs have been principally inferred by total annual
costs in the US [32,35] and are therefore mean and
approximate but the relative cost effectiveness remains
unchanged independently from the initial values chosen.
The relative cost-effectiveness of alternative strategies
assumes enormous economic implications multiplied by
billion examinations.
In addition, using ionizing testing, small individual risks
and costs multiplied by billion examinations become sig-
nificant population risk and costs. In 2002, 9.300.000 car-
diac perfusion scans performed in the US [4] and overall
costs for extra-risk of fatal and non-fatal cancer will be
$939.300.000 using Tc scan, double using Th scan (mean
$1.408.950.000) [35].
These results suggest that efforts should be done to orient
the patient towards non-ionizing testing.
Clinical and economic implications
Non-invasive nonionising strategies have the better cost-
effective profile in the management of low-intermediate
risk chest pain patients. Chest pain unit (CPU) manage-
ment is a useful and safe cost-efficacy alternative to hospi-
tal admission [39,40]. Stress test pre-discharge increases
the initial cost of assessment but the cost per patient cor-
rectly identified is lower than biochemical markers testing
strategy because the sensitivity of biochemical markers for
unstable angina remains poor and the risk of coronary
events is over 10–13% at 1-year follow-up [15,16]. Stress
imaging is more expensive than the ex-ECG but PhSE and
ex-Echo have a better cost effective value compared with
ex-ECG and myocardial stress SPECT. Costs of imaging
testing are now an unsustainable trajectory and things will
even worsen in the near future, with the forecast of 40-
fold increase of cardio computed tomography (CT) and
28-fold increase in stress echo within the year 2020
[41,42].
Social and environmental implications
Acute and long-term risks and costs of ionizing testing
seem to have enormous social and environmental impli-
cations, which ask for analyses and investigations. It is
commonly acknowledged that every effort should be
done to orient the patient towards the most appropriate
diagnostic techniques and to, when possible, non-ioniz-
ing testing [22-25]. Doses and risks associated with the
different diagnostic options represent an important aspect
to be considered when choosing a testing technique.
Moreover, the radioactive waste disposal has induced in
the last years increasing costs and the International
Atomic Energy Agency has urged the adoption of meas-
ures to avoid or reduce the radioactive waste production
because of social and environmental implications.
Medico-legal Implications
Use of radiation for medical examinations and tests is the
largest manmade source of radiation exposure and
become significant population risk and costs. [5].
For this reason, in Europe both the law [43] and the refer-
ral guidelines for medical imaging [25,44] recommend a
justified, optimized and responsible use of testing withCardiovascular Ultrasound 2008, 6:21 http://www.cardiovascularultrasound.com/content/6/1/21
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ionizing radiation. The Euratom directive 97/43 estab-
lishes that the indication and execution of diagnostic pro-
cedures with ionizing radiation should follow three basic
principles: the justification principle (article 3: "if an
exposure cannot be justified, it should be prohibited");
the optimization principle (article 4: according to ALARA
principle, "all doses due to medical exposures must be
kept as low as reasonably achievable") and the responsi-
bility principle (article 5: "both the prescriber and the
practitioner are responsible for the justification of the test
exposing the patient to ionizing radiation") [43]. Euro-
pean commission referral guidelines were released on
2001 in application of Euratom directive and evolved
from those previously published by the United Kongdom
(UK) Royal College of Radiology in 1998 [45]. They
explicitly state that a non-ionizing technique must be
used whenever it will give grossly comparable informa-
tion to an ionizing investigation. For instance, "because
magnetic resonance imaging (MRI) does not use ionizing
radiation, MRI should be preferred when both CT and
MRI would provide similar information and when both
are available" [25,44,46]. However, in spite of the existing
european law and european commission recommenda-
tions they are not so strictly reinforced, and at least 30%
of all ionizing testing procedures remain inappropriate in
clinical practice [25,44,45].
Common sense, deontological code, patients'rights, med-
ical imaging guidelines, euratom law, all coeherently and
concordantly suggest, encourage and order a responsible
and informed use of ionising testing. The current practice
clashes against these guidelines and laws [47,48]. The
combined effects of professional interests, defensive med-
icine, aggressive patients requests, and total lack of basic
information with frankly disinformed statements mini-
mizing risks present in the "best" medical literature set the
stage for a perfect legal storm. It is not possible to defend
physicians ignoring doses and risks of exams with high
radiation load.
Study limitations
The analysis is based on few studies performed in the ED
and only one of these compared the different strategies in
the same patients' population. However the results reflect
accuracies and prognostic values indicated in previous
studies and in meta-analyses performed in the overall
low-intermediate risk chest pain patient population. The
results of these studies could define new strategic
approach with enormous medical, social and environ-
mental implications.
Conclusion
Combined clinical outcomes and cost effectiveness-driven
testing strategy favors the use of stress echocardiography
as the first line diagnostic test and the driver to cardiac
catheterization in low-intermediate risk chest pain
patients. Widespread application of this approach in
health care system policies could result in substantial cost
saving, with a survival benefit of patients at-risk for future
major cardiac events and reduction of downstream long-
term risk and costs linked to radiation exposure. With all
its limitations, this study just aims to provide an empirical
evidence in support of the idea to favour and to incentive
further investigations and extends multi-disciplinary
empirical analyses in order to collect data useful for policy
makers, for all the other stakeholders and, especially, for
the society.
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